科学研究：
1、北京市自然科学基金面上项目，7222145，TTC17通过RAP1/CDC42通路调控乳腺癌转移的作用和机制研究，2022/01-2024/12；
2、国家自然科学基金面上项目，编号：81872398，长链非编码RNA-Lnc-712基因扩增诱导三阴性乳腺癌转移的作用及分子机制研究，2019/01-2022/12；
3、中国健康促进基金会课题，乳腺癌类器官模型药物敏感性测试与临床化疗疗效相关性研究；
4、辉瑞（中国）制药有限公司（研究者发起研究），全国多中心晚期乳腺癌临床流行病学调查；
5、GE（研究者发起研究），自动乳腺容积成像（ABUS）应用于乳腺癌诊断多中心研究；
6、北京乳腺病防治学会乳腺癌预防与诊治科研基金课题，内分泌治疗对绝经后乳腺患者血脂水平影响的研究；
7、中国医学基金会 肿瘤预防与科研基金课题，乳腺癌辅助治疗对患者月经状况影响的临床观察；
学术论文：
1. Ma ST, Wang DY, Liu YB, Tan HJ, Ge YY, Chi Y*, Zhang BL*. Prognostic factors of primary neuroendocrine breast cancer: A population-based study. Cancer Med. 2022 Jul;11(13):2533-2540. doi: 10.1002/cam4.4557. Epub 2022 May 2. PMID: 35499193.
2. 王杨，赵梓彤，宋咏梅，张柏林*. 脯氨酸羟化酶3在乳腺癌中的表达及其对乳腺癌细胞恶性表型的影响[J]. 中国医药导报, 2021, 18(28): 8-12,34.
3. Zhang L, Wang D, Wang Y, Ma J, Wang Y, Zhang B*. Patients with Lung Cancer Followed by Breast Cancer Have a Better Prognosis than Patients with these Cancers in the Opposite Order due to Differences in Pathological Components. EJMO. 2021; 5(2): 187-195.
4. Wei Zhang#, Bai-Lin Zhang#, Jian-Jun He*, Jin-Hu Fan*, Jing Li, Bin Zhang, Hong-Jian Yang, Xiao-Ming Xie, Zhong-Hua Tang, Hui Li, Jia-Yuan Li, Shu-Lian Wang, You-Lin Qiao, Rong Huang, Pin Zhang. Clinicopathological characteristics and treatment of young women with breast cancer in China: a nationwide multicenter 10-year retrospective study. Gland Surg. 2021;10(1):175-185. doi: 10.21037/gs-20-574. PMID: 33633974; PMCID: PMC7882316.
5. Zhang Y, Di X, Chen G, Liu J, Zhang B, Feng L, Cheng S, Wang Y. An immune-related signature that to improve prognosis prediction of breast cancer. Am J Cancer Res. 2021;11(4):1267-1285. PMID: 33948357; PMCID: PMC8085862.
6. Zhong-Li Du , Yang Wang, Ding-Yuan Wang, Li Zhang, Zhi-Min Bian, Ying Deng, Cheng-Shan Xu, Dong-Cai Lin, Li Xie, Yao Jia, Ji-Dong Gao*, Bai-Lin Zhang*. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database. Breast Cancer Res Treat. 2020; 183(2):429-438. doi: 10.1007/s10549-020-05776-2. PMID: 32647940.
7. 杜忠礼，许成山，边志民，张柏林*.三磷酸腺苷结合盒转运体C2基因遗传变异与TA方案新辅助化疗乳腺癌患者骨髓抑制的关联研究.中国肿瘤.2020,29(4):309-315.
8. 杜忠礼，许成山，边志民，彭明婷，李臣宾，封婷，徐晓洲，刘海净，张柏林*.有机阴离子转运多肽1B3基因遗传变异与TA方案新辅助化疗乳腺癌患者预后的关联研究. 中华肿瘤杂志.2019,41(8):587-593.（DOI: 10.3760/cma.j.issn.0253-3766.2019.08.006）
9. Wang Z, Liu W, Chen C, Yang X, Luo Y, Zhang B*. Low mutation and neoantigen burden and fewer effector tumor infiltrating lymphocytes correlate with breast cancer metastasization to lymph nodes. Sci Rep. 2019 Jan 22;9(1):253. doi:10.1038/s41598-018-36319-x. PubMed PMID: 30670769; PubMed Central PMCID:PMC6342949.
10. Tan L#, Mai D#, Zhang B#, Jiang X#, Zhang J, Bai R, Ye Y, Li M, Pan L, Su J, Zheng Y, Liu Z, Zuo Z, Zhao Q, Li X, Huang X, Yang J, Tan W, Zheng J, Lin D. PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Mol Cancer. 2019 Jan 12;18(1):9. doi: 10.1186/s12943-019-0940-3. PubMed PMID: 30636640; PubMed Central PMCID: MC6330501.
11. Zhang B#, Wu J, Zheng R, Zhang Q, Wang MZ, Qi J, Liu H, Wang Y, Guo Y, Chen F, Wang J, Lyu W, Gao J, Fang Y, Chen W, Wang X. Evaluation of menopausal status among breast cancer patients with chemotherapy-induced amenorrhea. Chin J Cancer Res. 2018 Aug;30(4):468-476. doi: 10.21147/j.issn.1000-9604.2018.04.10. PubMed PMID: 30210227; PubMed Central PMCID: PMC6129567.
12. 张柏林，吴金其，郑荣寿，齐军，刘海净，郭阳，王一澎，陈峰，吕文月，韩彬彬，王翔.女性乳腺癌发病危险因素的病例-对照研究.癌症进展.2017,15(4):395-398.
13. Zhang BL#, Sivasubramaniam PG#, Zhang Q, Wang J, Zhang B, Gao JD, Tang ZH, Chen GJ, Xie XM, Wang Z, Yang HJ, He JJ, Li H, Li JY, Fan JH, Wang X, Qiao YL. Trends in Radical Surgical Treatment Methods for Breast Malignancies in China: A Multicenter 10-Year Retrospective Study. Oncologist. 2015 Sep;20(9):1036-43. doi:10.1634/theoncologist.2014-0281. Epub 2015 Aug 7. PubMed PMID: 26253559; PubMed Central PMCID: PMC4571796.
14. Sivasubramaniam PG#, Zhang BL#, Zhang Q, Smith JS, Zhang B, Tang ZH, Chen GJ, Xie XM, Xu XZ, Yang HJ, He JJ, Li H, Li JY, Fan JH, Qiao YL. Breast Cancer Disparities: A Multicenter Comparison of Tumor Diagnosis, Characteristics, and Surgical Treatment in China and the U.S. Oncologist. 2015 Sep;20(9):1044-50. doi:10.1634/theoncologist.2014-0290. Epub 2015 Aug 3. PubMed PMID: 26240131; PubMed Central PMCID: PMC4571797.
15. 张柏林，张倩，Priya G. Sivasubramaniam，高纪东，方仪，王翔，张保宁，张斌，唐中华，谢小明，杨红建，何建军，李卉，李佳圆，范金虎，乔友林.中国年轻乳腺癌发病危险因素——多中心十年回顾性研究.中国肿瘤.2015,24(12):1043-1047.
16. Zhang B#, Love SM, Chen G, Wang J, Gao J, Xu X, Wang Z, Wang X. The safety parameters of the study on intraductal cytotoxic agent delivery to the breast before mastectomy. Chin J Cancer Res. 2014 Oct;26(5):579-87. doi:10.3978/j.issn.1000-9604.2014.10.06. PubMed PMID: 25400424; PubMed Central PMCID:PMC4220263.
17. Zhang X, Zhang B, Gao J, Wang X, Liu Z. Regulation of the microRNA 200b (miRNA-200b) by transcriptional regulators PEA3 and ELK-1 protein affects expression of Pin1 protein to control anoikis. J Biol Chem. 2013 Nov 8;288(45):32742-52. doi: 10.1074/jbc.M113.478016. Epub 2013 Sep 26. PubMed PMID: 24072701; PubMed Central PMCID: PMC3820908.
18. Yin Y, Zhang P, Xu BH, Zhang BL, Li Q, Yuan P, Cai RG, Wang JY, Wang X, Xu XZ. Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer. J Huazhong Univ Sci Technolog Med Sci. 2013 Apr;33(2):262-265. doi:10.1007/s11596-013-1108-9. Epub 2013 Apr 17. PubMed PMID: 23592141.
19. Love SM, Zhang W, Gordon EJ, Rao J, Yang H, Li J, Zhang B, Wang X, Chen G, Zhang B. A feasibility study of the intraductal administration of chemotherapy. Cancer Prev Res (Phila). 2013 Jan;6(1):51-8. doi: 10.1158/1940-6207.CAPR-12-0228. Epub 2012 Nov 20. Erratum in: Cancer Prev Res (Phila). 2013 May;6(5):506. PubMed PMID: 23169924.
20. Zhang BL#, Sun T, Zhang BN, Zheng S, Lü N, Xu BH, Wang X, Chen GJ, Yu DK, Lin DX. Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. Chin Med J (Engl). 2011 Jan;124(2):199-204. PubMed PMID: 21362365.
21. 张柏林，徐晓洲，王翔等. 芳香化酶抑制剂手术前治疗绝经后乳腺癌的疗效观察.中国癌症杂志.2010年;20(3):239-240.
22. 张柏林，刘海洁，张保宁. 乳腺癌新辅助内分泌治疗进展.医学研究杂志.2010;39(2):13-16.
23. 张柏林，徐晓洲，杨迅等.核心针活检在乳腺病变诊断和乳腺癌新辅助化疗中的应用价值.中华普通外科杂志; 2009,24(8): 631-633.
24. Zhang B#, Sun T#, Xue L, Han X, Zhang B, Lu N, Shi Y, Tan W, Zhou Y, Zhao D, Zhang X, Guo Y, Lin D. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis. 2007 May;28(5):1067-73. Epub 2006 Dec 20. PubMed PMID: 17183065.
25. Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T, Zhang B, Zhao D, Yang M, Yu D, Lin D. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis. 2007 Jun;28(6):1197-201. Epub 2006 Dec 6. PubMed PMID:17151091.
26. 张柏林，张保宁.蛋白质组学技术在乳腺癌研究中的应用.医学研究杂志. 2006;35(7), 76−78.
27. 张柏林，张保宁.乳腺癌化疗药物遗传学研究进展.医学研究杂志. 2006;35(8),83−84.
